Cargando…

Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL) effectively induce remission; however, disease recurrence remains a challenge. Due to the potential for antigen loss, antigen diminution, lineage switch or development of a secondary or treatment-related malignancy, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, George, Wang, Hao-Wei, Talleur, Aimee C, Shahani, Shilpa A, Yates, Bonnie, Shalabi, Haneen, Douvas, Michael G, Calvo, Katherine R, Shern, Jack F, Chaganti, Sridhar, Patrick, Katharine, Song, Young, Fry, Terry J, Wu, Xiaolin, Triplett, Brandon M, Khan, Javed, Gardner, Rebecca A, Shah, Nirali N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703409/ https://www.ncbi.nlm.nih.gov/pubmed/33246985 http://dx.doi.org/10.1136/jitc-2020-001563

Ejemplares similares

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
por: Faruqi, Aiman J., et al.
Publicado: (2022)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia
por: Petgrave, Yonique P, et al.
Publicado: (2023)

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
por: Zebley, Caitlin C., et al.
Publicado: (2021)

Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
por: Shalabi, Haneen, et al.
Publicado: (2020)

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms
por: Talleur, Aimee C., et al.
Publicado: (2023)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
por: Shalabi, Haneen, et al.
Publicado: (2015)

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
por: Jacoby, Elad, et al.
Publicado: (2016)

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
por: Epperly, Rebecca, et al.
Publicado: (2023)

Immunotherapy Associated Neurotoxicity in Pediatric Oncology
por: Shalabi, Haneen, et al.
Publicado: (2022)

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy
por: Maron, Gabriela M., et al.
Publicado: (2022)

Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management
por: Talamo, Laura, et al.
Publicado: (2017)

Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities
por: Rocco, Joseph M., et al.
Publicado: (2023)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023)

Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion
por: Jacoby, Elad, et al.
Publicado: (2015)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
por: Sugita, Mayumi, et al.
Publicado: (2023)

Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages
por: Wilson, Taylor L., et al.
Publicado: (2022)

A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia
por: Masih, Katherine E., et al.
Publicado: (2023)

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells
por: Holland, Elizabeth M., et al.
Publicado: (2021)

How I treat refractory CRS and ICANS after CAR T-cell therapy
por: Jain, Michael D., et al.
Publicado: (2023)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
por: Hsieh, Emily M., et al.
Publicado: (2022)

Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report
por: Deng, Lei, et al.
Publicado: (2022)

Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia
por: Liao, Wenjuan, et al.
Publicado: (2021)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
por: Sheykhhasan, Mohsen, et al.
Publicado: (2022)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

The Impacts of Car-Free Days and Events on the Environment and Human Health
por: Glazener, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5uv5ar4br9u2efshdqg29066h6